PhRMA says a new report released by IHS Markit backs a belief by some groups that the international pricing index for Medicare Part B drugs proposed by the Department of Health and Human Services would negatively impact patient access.
“One of the most common concerns is that patients in the United States will experience the same access restrictions that patients face abroad if the U.S. government proceeds with copying the flawed pricing practices of foreign governments,” PhRMA states in a recent article.
IHS Markit in its report suggests that patients with locally advanced and metastatic NSCLC would face a significant reduction in “aggregate survival gains” if the country adopted pricing models from other developed countries.
“Model outcomes indicate that American patients diagnosed with locally advanced and metastatic NSCLC between 2006 and 2017 have gained 201,700 life years in total due to access to innovative medicines,” IHS Markit says. “They would lose half of this survival benefits if they were living in other countries.”
Click here to read the PhRMA report.
To read the report from IHS Markit, click here.
